Abstract
We read the Comment by Amit Saxena and colleagues1 regarding the clinical efficacy and seroreactivity of an additional COVID-19 vaccine dose in patients with systemic lupus erythematosus with great interest.1 Samples were analysed at a mean of 44·7 days (SD 31·7) after the additional dose, and rates of breakthrough infections and anti-SARS-CoV-2 spike protein antibody titres were compared between those who did and did not receive an additional vaccine dose after the initial vaccination series. Although there were fewer breakthrough infections after the additional vaccine dose, there was no association between the antibody titre reported after that vaccine dose and infection.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
